COMP <GO>
INCY vs UNH // EV/EBITDA & P/E VALUATION
Incyte Corp. (NASDAQ) VS. UnitedHealth Group Incorporated (NYSE) • 15-METRIC TALLY: INCY 11
— UNH 4
▲ EV/EBITDA & P/E VALUATION LEADER: INCY
LAST: $120.39 (+3.07%) • MKT CAP: $23.68B
valuation
12.5x
LAST: $406.97 (-0.96%) • MKT CAP: $364.66B
valuation
16.4x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (INCY VS. UNH)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | INCY | UNH | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 92.80% | 88.57% | +4.23 | INCY | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 42.40% | 11.47% | +30.93 | INCY | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | 12.5x | 16.4x | -3.95 | INCY | /valuation <GO> |
| Free Cash Flow Yield | 4.99% | 6.48% | -1.49 | UNH | /fcf-yield <GO> |
| Operating Margin | 29.50% | 4.82% | +24.68 | INCY | /operating-margins <GO> |
| Net Profit Margin | 25.00% | 3.14% | +21.86 | INCY | /net-margins <GO> |
| Revenue Growth (YoY) | 21.20% | 6.46% | +14.74 | INCY | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.28% | -2.28 | UNH | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 10.04 | 3.12 | +6.92 | INCY | /balance-sheet <GO> |
| Piotroski F-Score Quality | 9/9 | 7/9 | +2.00 | INCY | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 6.90% | 6.74% | +0.16 | UNH | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 57.5 | 56.0 | +1.46 | INCY | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.01 | 0.33 | +0.68 | INCY | /macro-sensitivity <GO> |
| Forward P/E Multiple | 15.5x | 17.1x | -1.59 | INCY | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $23.68B | $364.66B | -$340.98B | UNH | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | INCY REV | UNH REV | INCY GROSS % | UNH GROSS % | INCY FCF | UNH FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $5.14B | $447.57B | 92.8% | 88.7% | $1.18B | $16.07B |
| FY 2024 | $4.24B | $400.28B | 92.6% | 88.3% | $144.5M | $20.70B |
| FY 2023 | $3.70B | $371.62B | 44.0% | 89.6% | $330.2M | $25.68B |
| FY 2022 | — | $324.16B | — | 89.6% | — | $23.40B |
| FY 2021 | — | $287.60B | — | 89.2% | — | $19.89B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
INCY // BETA 1.01
UNH // BETA 0.33